Sonoma Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 5, 2025
SNOA$1.14+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,681) | $(3,768) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 107 | 135 |
| Stock-based compensation | 134 | 447 |
| Deferred income taxes | 169 | 92 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 219 | (221) |
| Inventories, net | (679) | (93) |
| Prepaid expenses and other current assets | 1,547 | 546 |
| Deferred consideration | 142 | 161 |
| Operating lease, right-of-use assets | 136 | 99 |
| Accounts payable | 864 | (12) |
| Accrued expenses and other current liabilities | (1) | (226) |
| Deferred revenue | (140) | 33 |
| Withholding tax payable | 326 | 356 |
| Operating lease liabilities | (136) | (99) |
| Net cash provided by (used in) operating activities | 7 | (2,550) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (33) | (20) |
| Net cash used in investing activities | (33) | (20) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering expenses | 3,079 | 1,441 |
| Proceeds from exercise of employee stock options | 33 | – |
| Payments for fractional shares related to reverse-split | (1) | – |
| Principal payments on short-term debt | (323) | (387) |
| Net cash provided by financing activities | 2,788 | 1,054 |
| Effect of exchange rate on cash and cash equivalents | (654) | 102 |
| Net increase (decrease) in cash and cash equivalents | 2,108 | (1,414) |
| Cash and cash equivalents, beginning of period | 3,128 | 3,820 |
| Cash and cash equivalents, end of period | $5,236 | $2,406 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $8 | $15 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.